Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns

Guo, Jimin; May, Henning De; Franco, Stefan; Noureddine, Achraf; Tang, Lien; Brinker, C. Jeffrey; Kusewitt, Donna F.; Adams, Sarah F.; Serda, Rita E.

doi:10.1038/s41551-021-00795-w

Cited by 61 publications

(50 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very recently, Guo et al have developed a nanocomposite vaccine (Si-PEI-CpG-MPL) for OC immunotherapy by enhancing ATC stability and antigen presentation. [89] First, a nanoscale soluble silica shell was grown on OC cells by biomineralization and then has been cryogenically frozen to induce OC cell death to eliminate the possibility of tumorigenesis in vivo. To increase the presentation of OC antigens on ATC, a layer of polyethyleneimine (PEI) has been deposited on the silica surface, followed by loading with the immunoadjuvant cytosine-phosphate-guanine dideoxynucleotide motif (CpG) and monophosphoryl lipid A (MPL) (Figure 5C).…”

Section: Nanocomposite-based Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC

et al. 2022

View full text Add to dashboard Cite

Immunotherapy has revolutionized cancer treatment, dramatically improving survival rates of melanoma and lung cancer patients. Nevertheless, immunotherapy is almost ineffective against ovarian cancer (OC) due to its cold tumor immune microenvironment (TIM). Many traditional medications aimed at remodeling TIM are often associated with severe systemic toxicity, require frequent dosing, and show only modest clinical efficacy. In recent years, emerging nanomedicines have demonstrated extraordinary immunotherapeutic effects for OC by reversing the TIM because the physical and biochemical features of nanomedicines can all be harnessed to obtain optimal and expected tissue distribution and cellular uptake. However, nanomedicines are far from being widely explored in the field of OC immunotherapy due to the lack of appreciation for the professional barriers of nanomedicine and pathology, limiting the horizons of biomedical researchers and materials scientists. Herein, a typical cold tumor‐OC is adopted as a paradigm to introduce the classification of TIM, the TIM characteristics of OC, and the advantages of nanomedicines for immunotherapy. Subsequently, current nanomedicines are comprehensively summarized through five general strategies to substantially enhance the efficacy of immunotherapy by heating the cold OC. Finally, the challenges and perspectives of this expanding field for improved development of clinical applications are also discussed.

show abstract

Section: Nanocomposite-based Vaccinesmentioning

confidence: 99%

“…D) Percent and number of IP CD4+ and CD8+ T cells with naive (CD44− CD62L high), central memory (CD44+ CD62L high), and effector memory (CD44+ CD62L low) phenotypes. Reproduced with permission [89]. Copyright 2019, Springer Nature.…”

mentioning

confidence: 99%

Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Mirroring a TLR activation profile of Gram-negative bacteria [ 122 , 123 ], monophosphoryl6 lipid A and CpG ODN were bound to silicified murine ovarian tumor cells as a source of tumor antigen. Mice vaccinated with this combination of tumor cells and TLR agonists experienced significant tumor regression of established high-grade ovarian tumors [ 124 ]. Akin to the enhanced DC maturation following bacterial recognition by TLRs, tumor vaccine-treated DCs also experienced increased tumor antigen uptake and MHC expression, contributing to the induction of tumor-specific T cell immunity [ 124 , 125 , 126 ].…”

Section: Tlr–tlr Cross-talk and The Modulation Of Immune Responsementioning

confidence: 99%

Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression

Giurini

Madonna

Zloza

et al. 2022

Cancers

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are typical transmembrane proteins, which are essential pattern recognition receptors in mediating the effects of innate immunity. TLRs recognize structurally conserved molecules derived from microbes and damage-associated molecular pattern molecules that play an important role in inflammation. Since the first discovery of the Toll receptor by the team of J. Hoffmann in 1996, in Drosophila melanogaster, numerous TLRs have been identified across a wide range of invertebrate and vertebrate species. TLR stimulation leads to NF-κB activation and the subsequent production of pro-inflammatory cytokines and chemokines, growth factors and anti-apoptotic proteins. The expression of TLRs has also been observed in many tumors, and their stimulation results in tumor progression or regression, depending on the TLR and tumor type. The anti-tumoral effects can result from the activation of anti-tumoral immune responses and/or the direct induction of tumor cell death. The pro-tumoral effects may be due to inducing tumor cell survival and proliferation or by acting on suppressive or inflammatory immune cells in the tumor microenvironment. The aim of this review is to draw attention to the effects of TLR stimulation in cancer, the activation of various TLRs by microbes in different types of tumors, and, finally, the role of TLRs in anti-cancer immunity and tumor rejection.

show abstract

“…One feasible approach to solve this problem is to use a carrier to load PEI, thereby reducing its toxicity and side effects. Many materials can be used as carriers, such as mesoporous silica, polylactic acid, etc. ,− However, inorganic materials such as silica are difficult to degrade in vivo . Metabolites of polymers such as polylactic acid are prone to cause an inflammatory response in the body. , Although such inflammation may facilitate antigen presentation, it is easy to overreact and becomes dysfunctional due to the uncontrolled immune response to the normal tissues.…”

Section: Introductionmentioning

confidence: 99%

Efficient Tumor Immunotherapy through a Single Injection of Injectable Antigen/Adjuvant-Loaded Macroporous Silk Fibroin Microspheres

Fang

Cai

Lyu

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Synthetic or natural materials have been used as vaccines in cancer immunotherapy. However, using them as vaccines necessitates multiple injections or surgical implantations. To tackle such daunting challenges, we develop an injectable macroporous Bombyx mori (B. mori) silk fibroin (SF) microsphere loaded with antigens and immune adjuvants to suppress established tumors with only a single injection. SF microspheres can serve as a scaffold by injection and avoid surgical injury as seen in traditional scaffold vaccines. The macroporous structure of the vaccine facilitates the recruitment of immune cells and promotes the activation of dendritic cells (DCs), resulting in a favorable immune microenvironment that further induces strong humoral and cellular immunity. We have also modified the vaccine into a booster version by simply allowing the antigens to be adsorbed onto the SF microspheres. The booster vaccine highly efficiently suppresses tumor growth by improving the cytotoxic T lymphocyte (CTL) response. In general, these results demonstrate that the macroporous SF microspheres can serve as a facile platform for tumor vaccine therapy in the future. Since the SF microspheres are also potential scaffolds for tissue regeneration, their use as a vaccine platform will enable their applications in eradicating tumors while regenerating healthy tissue to heal the tumor-site cavity.

show abstract

Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns

Cited by 61 publications

References 45 publications

Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC

Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC

Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression

Efficient Tumor Immunotherapy through a Single Injection of Injectable Antigen/Adjuvant-Loaded Macroporous Silk Fibroin Microspheres

Contact Info

Product

Resources

About